SangHyun (Sean) Joo’s Post

Where, how and why can complex issues like circulating tumor DNA, and by extension, minimal residual disease help us to drive novel trial designs that are more patient friendly and concurrently can expedite the safety and efficacy evaluations of novel therapeutics? In this episode of the Syneos Health Podcast, Chief Scientific Officer Nick Kenny is joined by oncology experts Warl Harb and Patrick Kelly to discuss how circulating tumor DNA (ctDNA) is transforming cancer treatment and clinical trial design, and its potential to drive more patient-centric, adaptive clinical trials. Listen to the full episode: https://ow.ly/lOTl30sHL38

Where, how and why can complex issues like circulating tumor DNA, and by extension, minimal residual disease help us to drive novel trial designs that are more patient friendly and concurrently can expedite the safety and efficacy evaluations of novel therapeutics? In this episode of the Syneos Health Podcast, Chief Scientific Officer Nick K. is joined by oncology experts Wael Harb, MD, MBA and Patrick Kelly to discuss how circulating tumor DNA (ctDNA) is transforming cancer treatment and clinical trial design, and its potential to drive more patient-centric, adaptive clinical trials. Listen to the full episode: https://lnkd.in/eE95dgJP #SyneosHealth

I’m excited to announce the latest episode of the Syneos Health Podcast, where I had the pleasure of joining Dr. Nick Kenny and Dr. Patrick Kelly to discuss a game-changing innovation in oncology: circulating tumor DNA (ctDNA) and its role in transforming cancer treatment. In this episode, we explore how ctDNA is reshaping oncology trials by providing real-time insights into tumor dynamics, allowing for more precise, patient-friendly clinical trial designs. We also dive into the concept of minimal residual disease (MRD) and its potential to revolutionize early-phase drug development. Tune in to learn how ctDNA is driving a more personalized, evidence-based approach to cancer care that could accelerate drug development and approval processes. 🎙️ Listen now and discover how this cutting-edge technology is helping us bring better treatments to patients faster. #Oncology #CancerTreatment #ctDNA #MRD #DrugDevelopment #PrecisionMedicine #SyneosHealth #ClinicalTrials #InnovationInOncology #CancerResearch

🎥 Good news! Our latest webinar is now available to watch on demand! In it, you'll learn all about the latest advancements in organ-on-a-chip for cancer research and drug discovery. This webinar will not only cover capturing the tumor microenvironment (TME) in hepatocellular carcinoma in vitro but will explore how MIMETAS can help put therapeutic targets in immuno-oncology into patient context.   In this webinar, you will: - Gain unparalleled insights into replicating TME dynamics in vitro. - Engage in meaningful dialogue about TME complexities, focusing on angiogenesis, stroma, and immune responses. - Understand the impact of TME variables on the success of existing treatments. - Discover how partnership with MIMETAS can impact your oncology research, speeding up discovery and improving therapy prediction accuracy.   Watch the webinar here: https://lnkd.in/eBpNv8YE #CancerResearch #Immunooncology #OncologyResearch

At #AmplityHealth, our contract sales, medical, and communications experts have a front-row seat in advancing #immunotherapy and #precisionmedicine to combat cancer more effectively with our biopharma clients. Here are some key highlights from #ASCO24 Day 1: - Discussion of newly FDA-approved oncology agents - Presentation of 5 years of data from the CROWN study comparing lorlatinib and crizotinib in new patients with advanced ALK-positive non-small cell lung cancer - Analysis of research into whether circulating tumor DNA can help predict the effectiveness of neoadjuvant chemotherapy and evaluate the prognosis for those with early breast cancer View our full Day 1 summary and join our mailing list for updates: https://lnkd.in/gA3s6Gh7

Where, how and why can complex issues like circulating tumor DNA, and by extension, minimal residual disease help us to drive novel trial designs that are more patient friendly and concurrently can expedite the safety and efficacy evaluations of novel therapeutics? In this episode of the #SyneosHealth Podcast, Chief Scientific Officer Nick Kenny is joined by oncology experts Warl Harb and Patrick Kelly to discuss how circulating tumor DNA (ctDNA) is transforming cancer treatment and clinical trial design, and its potential to drive more patient-centric, adaptive clinical trials. Listen to the full episode: https://lnkd.in/gwQBY63x #SyneosHealthLife #WorkHereMattersEverywhere #ClinicalCareers 

In business news, BeiGene has proposed a name change to BeOne Medicines. The new logo is clever. As per their explanation: The word “Onc” spelled in red within “One” illustrates our redoubled commitment to oncology; and The power button within the last “e” represents our always “on” approach in pursuing novel medicines that turn cancer “off” by disrupting key drivers of cancer cell growth and survival, harnessing the body’s immune system to attack tumors, and targeting specific biomarkers of cancer. The tilted angle of the button embodies our path which is not always straight-forward as we push the boundaries of science. https://lnkd.in/eDsUDdXy

Where, how and why can complex issues like circulating tumor DNA, and by extension, minimal residual disease help us to drive novel trial designs that are more patient friendly and concurrently can expedite the safety and efficacy evaluations of novel therapeutics?   In this episode of the #SyneosHealth Podcast, Chief Scientific Officer Nick Kenny is joined by oncology experts Warl Harb and Patrick Kelly to discuss how circulating tumor DNA (ctDNA) is transforming cancer treatment and clinical trial design, and its potential to drive more patient-centric, adaptive clinical trials. Listen to the full episode: https://lnkd.in/gnuCZK5U   #SyneosHealthLife #WorkHereMattersEverywhere #ClinicalCareers 

Where, how and why can complex issues like circulating tumor DNA, and by extension, minimal residual disease help us to drive novel trial designs that are more patient friendly and concurrently can expedite the safety and efficacy evaluations of novel therapeutics? In this episode of the #SyneosHealth Podcast, Chief Scientific Officer Nick Kenny is joined by oncology experts Warl Harb and Patrick Kelly to discuss how circulating tumor DNA (ctDNA) is transforming cancer treatment and clinical trial design, and its potential to drive more patient-centric, adaptive clinical trials. Listen to the full episode: https://lnkd.in/d22H2ae2 #SyneosHealthLife #WorkHereMattersEverywhere #ClinicalCareers